Reporting from the frontiers of health and medicine

Adrian Cole

15 articles

Founder & Editor-in-Chief, Bioengineering & Methods

Adrian.Cole@genomethods.org

Adrian Cole is the Founder and Editor-in-Chief of GenoMethods, where he writes about bioengineering, genome and cell engineering, synthetic biology, computational biology and emerging research methods. His editorial approach focuses on how technologies actually work, how they are validated and where the evidence stops supporting the claim.

Updated: 18.09.2026

 
Adrian Cole was born in Eugene, Oregon, and later moved to Seattle, where an early interest in the intersection of engineering, biology and medicine led him to study bioengineering at the University of Washington. He graduated from the university’s bioengineering program after working across coursework and project-based research involving biological systems, quantitative analysis, molecular technologies and the engineering principles used to turn experimental concepts into practical research tools; the experience shaped his lasting interest in the difference between a technically impressive prototype and a method that can survive real-world testing. After university, Cole worked in a university research laboratory and later with multidisciplinary biotechnology teams operating at the boundary between experimental biology, engineering and early-stage product development, where his work exposed him to assay development, biological measurement, research instrumentation, data interpretation and the practical problems that arise when laboratory techniques are transferred between researchers or scaled beyond a single experimental setting. He subsequently spent time with an early-stage life-science organisation focused on translating research concepts into usable biotechnology workflows, an experience that pushed him toward a broader interest in reproducibility, validation, workflow design and the gap between what a technology promises in principle and what it can reliably deliver in practice.

Over time, Cole moved increasingly toward scientific analysis, technical editing and explanatory writing, finding that many of the most important biotechnology stories were difficult to understand not because the underlying science was inaccessible, but because coverage often skipped the methodological details that determine whether a result is convincing. He now leads GenoMethods while writing and editing across bioengineering, genome editing, cell engineering, synthetic biology, genomics, sequencing technologies, computational biology, AI-assisted biological research, research instrumentation and emerging experimental platforms, with particular attention to technologies that can influence drug discovery, diagnostics and advanced therapies. His editorial perspective is deliberately methods-first: before treating a new platform as a breakthrough, he looks at experimental design, controls, sample size, benchmarking, reproducibility, technical limitations, competing approaches and whether the reported improvement is meaningful outside the conditions in which it was originally demonstrated. For readers, that means his work is designed not simply to explain what a new biotechnology platform claims to do, but to show how it works, which evidence supports it, what remains uncertain, what could cause it to fail and what additional data would materially change the assessment. 

·

Areas of Expertise

  • Bioengineering The application of engineering principles and quantitative methods to biological systems, biotechnology, medicine and the development of technologies that interact with living systems.
  • Genome Editing Methods for making targeted alterations to genetic material, including CRISPR-based systems, base editing, prime editing and related genome-engineering technologies.
  • Computational Biology The use of computation, mathematical modelling, algorithms and biological data analysis to investigate biological systems and support experimental research.

15 latest articles by Adrian Cole